Literature DB >> 6216909

Concurrent development of preleukaemic, lymphoproliferative and plasma cell disorders.

B R Greenberg, C Miller, R D Cardiff, M R MacKenzie, P Walling.   

Abstract

A patient is described who presented with a combined preleukaemic, lymphoproliferative and plasma cell disorder. These disorders were not related to cytotoxic therapy. The clonal nature of the lymphoid component was demonstrated by lymphocyte surface marker studies and the clonal nature of the plasma cell component by immunoperoxidase studies. Since the involved lymphoid and plasma cells contained different heavy and light chains, they were felt to originate from two separate B cell clones not related to the clone responsible for the preleukaemic component.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6216909     DOI: 10.1111/j.1365-2141.1983.tb01994.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Monoclonal gammopathy in chronic myeloproliferative disorders.

Authors:  T Economopoulos; J Economidou; E Papageorgiou; J Dervenoulas; C Christodoulides; V Pappa; D Karakassis; C Terzoglou; S Athanassiadou; G Chalevelakis
Journal:  Blut       Date:  1989-01

2.  Lymphoproliferations in the bone marrow: identification and evolution, classification and staging.

Authors:  R Bartl; B Frisch; R Burkhardt; K Jäger; R Pappenberger; G Hoffmann-Fezer
Journal:  J Clin Pathol       Date:  1984-03       Impact factor: 3.411

3.  Immune abnormalities in myelodysplastic syndromes.

Authors:  T Economopoulos; J Economidou; G Giannopoulos; C Terzoglou; E Papageorgiou; J Dervenoulas; P Arseni; J Hadjioannou; S Raptis
Journal:  J Clin Pathol       Date:  1985-08       Impact factor: 3.411

4.  Coexistence of essential thrombocythemia and multiple myeloma.

Authors:  F Prósper; J R Borbolla; J Rifón; B Cuesta; J Fernández; A Pinacho; E Rocha
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.